KRAS and non-small cell lung carcinoma: We previously compared gene mutation and basal gene and protein expression among 63 NSCLC cell lines and discovered that mesenchymal NSCLC cell lines were more sensitive to Plk1 inhibitors than were epithelial cell lines in vitro and in vivo; however, KRAS, TP53, and MET mutations did not consistently predict sensitivity.